Clinical Observation of Rituximab,Lenalidomide Combined with Obutinib in the Treatment of Elderly Patients with Diffuse Large B-cell Lymphoma
Objective:To investigate the clinical effect of rituximab,lenalidomide combined with aubutinib in the treatment of el-derly patients with diffuse large B-cell lymphoma.Methods:Sixty elderly patients with diffuse large B cell lymphoma admitted to 2020.5-2022.6 were divided into control group and observation group,with 30 patients each.The control group received chemotherapy with R-mini-CHOP regimen,and the observation group received rituximab,lenalidomide combined with obutinib regimen,to compare the relevant indicators between the two groups.Results:Patients in the observation group had higher rates of objective response than the control group(P＜0.05);they had higher CD3+and CD4+levels,and lower CD8+levels than the control group(P＜0.05);the overall inci-dence of toxic effects during treatment was lower than in the control group(P＜0.05).The median PFS was 14.9(95％CI 12-17)and 5.8(95％CI 4-7)(P＜0001),and the median OS was 20.1(95％CI 16-22)and 7.5(95％CI 5-9)(P＜0001).Conclusion:Treatment with ritux-imab and lenalidomide combined with obutinib can reduce the immune damage in elderly patients with diffuse large B cell lymphoma,with a certain safety profile and significant clinical efficacy.
Diffuse large B-cell lymphomaOld ageRituximabLenalidomideObutinib
NETL
NSTL
万方数据
